Author(s): Rolfs, Prof. Arndt, MD, Zimran, Ari, MD, Cozma, Dr. rer. nat. Claudia, MD, Yum, Mi-Sun, Heo, Sun Hee, Kim, Taeho, Jin, Hee Kyung, Bae, Jae-sung, Seo, Go Hun, Oh, Arum, Yoon, Hee Mang, PhD, Lim, Hyun Taek, Kim, Hyo-Won, MD, PhD, Ko, Tatiana, Lim, Hyeong-Seok, Osborn, Mark, PhD, Kim, Yoon-Myung, Tolar, Jakub, Lee, Pr. Beom Hee, Yoo, Han-Wook, MD, PhD
Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy
While ambroxol has been in medical use for respiratory diseases for over 40 years, its recently understood mode of action suggests a wider applicability. For Gaucher disease (GD), a metabolic disorder, ambroxol has now been shown to improve neurological symptoms, and to reduce the levels of CENTOGENE’s GD-specific biomarker Lyso-Gb1. The study was published in Journal of Medical Genetics.
Read publication
